Dimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
Open PDF
| Stock | Dimerix Ltd (DXB.ASX) |
|---|---|
| Release Time | 17 Jul 2026, 9:01 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Dimerix Secures Non-Dilutive Funding for Clinical Trials
Key Points
- AU$10 million secured to support DMX-200 commercial manufacturing
- Dimerix funded through ACTION3 Phase 3 trial completion
- Phase 2 trial initiation for DMX-652 in acute kidney injury
Full Summary
Dimerix Ltd, a clinical-stage biopharmaceutical company, has secured a AU$10 million non-dilutive loan facility from SKIPTAN Pty Ltd, an associate of a substantial shareholder, to support its clinical trials. This funding will aid in commercial manufacturing of DMX-200, expanded access programs, and the initiation of a Phase 2 trial for DMX-652, a new asset for acute kidney injury. Dimerix is now funded through the completion of the ACTION3 Phase 3 trial for DMX-200 and the Phase 2 trial for DMX-652. Negotiations are ongoing for up to an additional AU$40 million in non-dilutive funding to extend the cash runway beyond these trials.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In